ScreenerHero

CGEN Compugen Ltd.

NAS · US · Healthcare · Biotechnology · cgen.com
2.150USD-3.15%Mkt Cap: 203.66M $P/E: 5.66

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap203.66M USD
Enterprise Value88.01M USD
Revenue (TTM)74.00M USD
Gross Profit63.51M USD
Net Income (TTM)35.34M USD
Revenue/Share0.79 USD
Last Price2.150 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees75
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)5.66
P/E (Forward)-6.05
PEG1.29
EV/EBITDA2.87
EV/Revenue1.19
P/S2.84
P/B2.37
EPS (TTM)0.36
EPS (Forward)-0.37
52W Range
1.40041% of range3.240
52W High3.240 USD
52W Low1.400 USD
Profitability
Gross Margin87.29%
Oper. Margin-339.62%
EBITDA Margin41.45%
Profit Margin48.57%
ROE34.40%
ROA22.57%
Growth
Revenue Growth107.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF31.63M USD
CapEx (TTM)306.00K USD
FCF Margin30.02%
FCF Yield10.91%
Net Debt-122.28M USD
Net Debt/EBITDA-3.99
Balance Sheet
Debt/Equity0.03
Current Ratio5.72
Quick Ratio5.72
Book Value/Sh0.94 USD
Cash/Share1.32 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.600 USD
Upside (mean)+114.0%
Target Range4.000 USD – 6.000 USD
4.000+114.0% to mean6.000
# Analysts5
Ownership
Shares Out.94.72M
Float94.51M
Insiders0.18%
Institutions15.22%
Short Interest
Short Ratio7.8d
Short % Float2.50%
Short % Out.2.50%
Shares Short2.37M
Short (prev mo.)3.03M
Technical
SMA 502.450 (-12.3%)
SMA 2002.261 (-4.9%)
Beta2.79
S&P 52W Chg16.45%
Avg Vol (30d)229.29K
Avg Vol (10d)155.76K
Technical Indicators
RSI (14)33.4
MACD-0.0614
MACD Signal-0.0346
MACD Hist.-0.0268
BB Upper2.587 USD
BB Middle2.388 USD
BB Lower2.188 USD
BB Width16.70%
ATR (14)0.0960 USD
Vol Ratio (20d)1.17x